Compare · LLY vs MPLT
LLY vs MPLT
Side-by-side comparison of Eli Lilly and Company (LLY) and MapLight Therapeutics Inc. (MPLT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LLY and MPLT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.06T, about 1737.5x MPLT ($608.9M).
- Over the past year, LLY is up 49.7% and MPLT is down 23.6% - LLY leads by 73.3 points.
- LLY has been more active in the news (12 items in the past 4 weeks vs 7 for MPLT).
- LLY has more recent analyst coverage (25 ratings vs 14 for MPLT).
- Company
- Eli Lilly and Company
- MapLight Therapeutics Inc.
- Price
- $1124.58-2.08%
- $13.96+1.34%
- Market cap
- $1.06T
- $608.9M
- 1M return
- -5.26%
- +14.75%
- 1Y return
- +49.74%
- -23.56%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2025
- News (4w)
- 12
- 7
- Recent ratings
- 25
- 14
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest LLY
- Lilly to participate in Morgan Stanley 24th Annual Global Healthcare Conference
- New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity
- Lilly to acquire Merida Biosciences to advance treatments for serious autoimmune and allergic diseases
- FDA approves Lilly's Mounjaro (tirzepatide) to reduce cardiovascular risk in adults with type 2 diabetes
- Zepbound linked to lower healthcare costs in adults over age 55 with obesity according to a real-world study
- Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.
- Director Sulzberger Gabrielle was granted 4 shares, increasing direct ownership by 0.14% to 3,004 units (SEC Form 4)
- Director Luciano Juan R was granted 13 shares, increasing direct ownership by 0.08% to 16,918 units (SEC Form 4)
- Director Fyrwald J Erik was granted 8 shares, increasing direct ownership by 0.01% to 75,418 units (SEC Form 4)
- Director Alvarez Ralph was granted 10 shares, increasing direct ownership by 0.02% to 55,745 units (SEC Form 4)
Latest MPLT
- Chief Discovery Officer Kreitzer Anatol was granted 6,020 units of Voting Common Stock, increasing direct ownership by 3% to 180,926 units (SEC Form 4)
- CAO and Interim CFO Gillis Jonathan was granted 8,242 units of Voting Common Stock, increasing direct ownership by 6% to 152,482 units (SEC Form 4)
- Chief Executive Officer Kroeger Christopher A. was granted 23,145 units of Voting Common Stock, increasing direct ownership by 2% to 1,269,600 units (SEC Form 4)
- General Counsel Hanson Kristopher was granted 7,730 units of Voting Common Stock, increasing direct ownership by 5% to 153,553 units (SEC Form 4)
- Chief Medical Officer Foff Erin Pennock was granted 13,360 units of Voting Common Stock, increasing direct ownership by 4% to 312,261 units (SEC Form 4)
- Chief Scientific Officer Lillie James Woodruff was granted 7,730 units of Voting Common Stock, increasing direct ownership by 4% to 210,110 units (SEC Form 4)
- Large owner Catalyst4, Inc. bought $50,072,000 worth of Voting Common Stock (4,400,000 units at $11.38) (SEC Form 4)
- SEC Form 10-Q filed by MapLight Therapeutics Inc.
- MapLight Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure
- MapLight Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update